How will the patent extension affect availability of keytruda?

Impact of Patent Extension on Keytruda Availability

The patent extension for Keytruda (pembrolizumab) has significant implications for its availability in the market. Keytruda, developed by Merck, is a widely used immunotherapy medication for various types of cancers, including melanoma, lung cancer, and others [1].

What happens if the patent isn't challenged?

If the patent isn't challenged, the patent extension would grant exclusivity to Merck until 2034, allowing them to maintain a monopoly on the market. This would likely continue to limit the availability of biosimilars (bio-identical versions of Keytruda), which could enter the market once the patent expires.

Why are companies challenging this patent?

Several pharmaceutical companies, including Sandoz and Pfizer, have challenged Merck's patent extension. If these challenges are successful, it could lead to earlier entry of biosimilars into the market [2].

How does this affect biosimilar competition?

A longer patent extension would hinder biosimilar competition, as it would prevent biosimilars from entering the market until 2034. This could limit patient access to affordable treatments and hinder innovation in the field of cancer immunotherapy.

Who stands to benefit from a patent extension?

Merck would be the primary beneficiary of a patent extension, as it would continue to enjoy exclusivity in the market and maintain its market share.

What are the implications for patients?

Patients with cancer who rely on Keytruda may face delays in accessing more affordable treatments if the patent extension remains in place. This could have significant consequences for individuals who may be unable to afford the high cost of Keytruda.

When does exclusivity expire?

If the patent is not challenged, the patent extension for Keytruda would currently expire in 2034. However, if the challenges are successful, the exclusivity period may be shortened.

What happens if biosimilars enter before the patent expiry?

If biosimilars enter the market before the patent expires, patients may have access to more affordable treatment options. However, this would depend on the regulatory approval process and the actions of the patent holders.

Sources:

[1] https://www.drugpatentwatch.com/patent/US-7759249B2 (Merck's Keytruda patent)

[2] https://www.bioworld-web.com/articles/2023/01/merck-challenge-loses-appeal-keytruda-patent (Sandoz and Pfizer's patent challenges)